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Abstract Pharmacological targeting of transcription factors holds great promise for the
development of new therapeutics, but strategies based on blockade of DNA binding, nuclear
shuttling, or individual protein partner recruitment have yielded limited success to date.
Transcription factors typically engage in complex interaction networks, likely masking the effects of
specifically inhibiting single protein-protein interactions. Here, we used a combination of genomic,
proteomic and biophysical methods to discover a suite of protein-protein interactions involving the
SOX18 transcription factor, a known regulator of vascular development and disease. We describe a
small-molecule that is able to disrupt a discrete subset of SOX18-dependent interactions. This
compound selectively suppressed SOX18 transcriptional outputs in vitro and interfered with
vascular development in zebrafish larvae. In a mouse pre-clinical model of breast cancer, treatment
with this inhibitor significantly improved survival by reducing tumour vascular density and
metastatic spread. Our studies validate an interactome-based molecular strategy to interfere with
transcription factor activity, for the development of novel disease therapeutics.
DOI: 10.7554/eLife.21221.001
Introduction
The SOXF group (SOX7,  17 and  18) of transcription factors (TFs) are key regulators of endothelial
cell differentiation during development (Franc¸ois et al., 2008; Corada et al., 2013; Hosking et al.,
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2009; Matsui et al., 2006; Cermenati et al., 2008; Herpers et al., 2008), and are thus critical for
the formation of vasculature. Mutation or deletion of SoxF genes compromises arteriovenous specifi-
cation, blood vascular integrity and lymphangiogenesis, and inhibits tumour growth and metastasis
in animal models of cancer (Duong et al., 2012; Yang et al., 2013; Zhang et al., 2009;
Young et al., 2006). More recently, high levels of SOX18 have been associated with poor prognosis
for cancer in human patients (Eom et al., 2012; Pula et al., 2013; Jethon et al., 2015). Pharmaco-
logical inhibition of SOX18 protein function therefore presents a potential avenue for management
of the vascular response in cancer.
Transcription factors often operate in mutually redundant families, thwarting conventional
approaches to developing transcription factor-based therapies. Any attempt to develop pharmaceu-
tically useful SOX18 inhibitors must overcome two obstacles — first, that SOX18 loss of function is
compensated by the action of the remaining SOXF (Hosking et al., 2009), and second, that each
SOXF factor is likely to have several partners that may themselves act redundantly. To address these
challenges, we sought to develop a means of broad-scale functional inhibition of SOX18 transcrip-
tion factor through the simultaneous interference with multiple SOX18 protein-protein interactions
(PPIs).
SOX proteins activate individual target genes by recruiting specific interacting partners
(Sarkar and Hochedlinger, 2013), but only two protein-protein interactions for the SOXF group
(SOX18-MEF2C and SOX17-OCT4) have been identified to date (Hosking et al., 2001; Jauch et al.,
2011). We first mapped the SOX18 interactome (the network of SOX18 interacting partners), using
a combination of unbiased proteomic technologies. Chromatin immunoprecipitation coupled to
mass spectrometry (ChIP-MS) provided a first-pass screen for proteins associated with chromatin-
bound SOX18 in human umbilical vein endothelial cells (HUVECs) (Mohammed et al., 2013), then,
ALPHA-Screen resolved SOX18-dependent complexes into pairwise interactions using in vitro trans-
lated full-length proteins (Figure 1A) (Mureev et al., 2009; Kovtun et al., 2011; Sierecki et al.,
2013, 2014; Gambin et al., 2014). ChIP-MS analysis revealed 289 proteins, representing a variety of
gene ontology (GO) classes of molecular function, that associate directly or indirectly with SOX18
(Figure 1B, Figure 1—figure supplement 1A–C). To increase our chance of identifying direct inter-
actors, we focused on proteins known to be nucleic acid and/or protein binding (Figure 1B, purple).
From this subset, we chose eight known transcription factors, helicases, co-repressors, RNA binding
and DNA-repair molecules (Figure 1—figure supplement 1A,B). Using ALPHA-Screen, we observed
that SOX18 interacts with itself, and also forms pairwise interactions with DDX1, DDX17, ILF3,
STAT1, TRIM28, and XRCC5 (Figure 1C, left column ‘+’, Figure 1—figure supplement 1D).
In addition, we studied potential pairwise interactions of 6 well-known TFs able to regulate endo-
thelial cell function (ESR1, NR2F2, RBPJ, SOX7, SOX17 and CTNNB1), and the only identified SOX18
protein partner MEF2C (Hosking et al., 2001). The well-characterized SOX9 homo-dimer
(Bernard et al., 2003) was included as a positive control to validate the ALPHA-Screen signal (Fig-
ure 1—figure supplement 1D). SOX18 was found to interact with all endothelial transcription fac-
tors tested, with the possible exception of SOX17 and CTNNB1, which showed a binding affinity
below the arbitrary threshold (Figure 1C, ‘-’).
Having identified an array of proteins able to interact with SOX18, we then went on to test the
activity of a small-molecule compound, Sm4 (Figure 1—figure supplement 1E), on these interac-
tions. Sm4, derived from a natural product found in the brown alga Caulocystis cephalornithos, was
identified in a high-throughput screen for potential SOX18 blockers (Fontaine et al., to be published
in full elsewhere). We found that Sm4 significantly disrupted 6 out of the 12 validated SOX18 inter-
actions (Figure 1C, right column), with IC50 values ranging from 3.3 mM for SOX18-SOX18 to 65.9
mM for SOX18-RBPJ dimers (Figure 1D, Figure 1—figure supplement 1F). To assess a differential
effect of Sm4 on the distinct SOXF members, we explored an additional set of PPIs between all
three SOXF proteins and MEF2C, RBPJ and OCT4 (Figure 1—figure supplement 2). Like SOX18,
SOX7 is able to interact with RBPJ and SOX18 itself, both of which interactions are at least partially
disrupted by Sm4. We further found that all three SOXF proteins can form a heterodimer with
OCT4, whereas only the SOX17-OCT4 interaction is affected by Sm4. Importantly, neither SOX7 nor
SOX17 have the capacity to form a homodimer, and thus this component of Sm4 mode of action is
highly specific to SOX18-SOX18 interaction. Further corroborating this, SOX9 homodimerization was
unperturbed by Sm4 at up to 200 mM (Figure 1C,D, Figure 1—figure supplement 1D). These
results show that Sm4 selectivity leans towards a subset of SOX18-associated PPIs, but has the
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Figure 1. Mapping of SOX18 interactome and disruption of interactions by Sm4. (A) Schematic of the experimental strategy to deconvolute SOX18-
dependent protein-protein interactions (PPIs) combining Chromatin immunoprecipitation-mass spectrometry (ChIP-MS) and Amplified Luminescent
Proximity Homogeneous Assay (ALPHA-Screen) methods. (B) GO-term analysis for molecular function on the 289 proteins identified by SOX18-cMyc
ChIP-MS in human umbilical vein endothelial cells (HUVECs). Non-specific interactors found in Myc-tag only transfected cells were subtracted. Proteins
Figure 1 continued on next page
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capability to interfere with SOX7 or SOX17 protein partner recruitment. This feature of Sm4 is
potentially advantageous in preventing SOXF redundancy mechanism (Hosking et al., 2009;
Kim et al., 2016)
To assess how SOX18 PPI disruption translates into transcriptional dysregulation, we next per-
formed a combination of genome-wide RNA-seq and ChIP-seq analyses in HUVECs. The most com-
mon binding motif identified from the SOX18 ChIP-seq peaks corresponds to the previously
reported SOX motif 5’-AACAAT-3’(Figure 2—figure supplement 1A) and the validity of this ChIP-
seq dataset was further confirmed by GO term analysis and identification of known SOX18 target
genes such as Prox1 and Vcam1 (Supplementary file 1a, Figure 2—figure supplement 1B)
(Franc¸ois et al., 2008; Hosking et al., 2004). We compared the global transcriptional effect of Sm4
treatment to DMSO control in SOX18 overexpressing cells (Figure 2—figure supplement 1C–E,
Supplementary file 1b), and overlaid this list of differentially expressed genes with the SOX18 ChIP-
seq dataset. Using this overlay, we calculated the distance between the transcription start site (TSS)
of a gene and a TF binding event, as a proxy for the likelihood of direct transcriptional regulation.
To be able to analyse how this distance is altered by Sm4, we established a reference distance
between the TSS of a random gene set and SOX18 binding events (Figure 2A). In parallel, we per-
formed the same analysis for SOX7 (generated in-house), and for all seven transcriptional regulators
available from the ENCODE consortium (cMYC, GATA2, c-FOS, c-JUN, CTCF, EZH2, MAX, c-MYC).
This allowed us to distinguish between transcriptional targeting of SOX18 and potential off target
effects on other endothelial specific transcription factors.
The cumulative SOX18 peak-to-TSS distance demonstrated that, overall, SOX18 peaks are 3.6
fold closer (p-value<0.001) to the TSS of Sm4 down-regulated genes than to randomly distributed
TSSs (Figure 2B, top left). These results are an indirect indication that the Sm4 affected genes are
dysregulated through a specific effect on SOX18 transcriptional activity. This correlation was not
observed for 7 of the other transcription factors tested (Figure 2B, Figure 2—figure supplement
1F, Supplementary file 1c), signifying that Sm4 does not have an off-target effect on these TFs
activity. Interestingly, the TSS of Sm4 down-regulated genes were 2.05 fold closer to c-JUN binding
events (p-value=0.011, Supplementary file 1c). Although only mildly significant, this could suggest
possible co-regulation by SOX18 and c-JUN on this subset of Sm4 down-regulated genes. Indeed,
analysis of known motifs in SOX18 ChIP-seq peaks revealed an over-representation of c-JUN binding
motifs (3.23% of SOX18 peaks, p-value=1e-302) and ALPHA-Screen analysis further established that
SOX18 and c-JUN could physically interact (Figure 2—figure supplement 2). We found that the
expression levels of the other TFs tested were unaltered by Sm4 treatment (Supplementary file 1c).
This is an important observation because it demonstrates that there was no bias introduced by an
off-target modulation of the transcript levels for these transcription factors in presence of Sm4.
To address the issue of potential transcriptional off-target effects of Sm4 on SOX TF family mem-
bers we focused on closely related SOXF and SOXE proteins. Sm4 did not affect the transcriptional
activity of either SOX17 or SOX9 proteins at any tested concentration (50 mM) in cell-based
reporter assays (Figure 2—figure supplement 3) (Robinson et al., 2014; Lefebvre et al., 1997).
Figure 1 continued
with nucleic acid binding or protein binding capacity (purple) were considered for consecutive direct interaction studies to enhance likeness of
identifying direct interactors. (C) Left column: heatmap representation of SOX18 pairwise PPIs as tested by ALPHA-Screen, on a selection of ChIP-MS
SOX18 associated proteins, endothelial transcription factors and positive/negative control proteins. Right column: heatmap representation of Sm4
activity on SOX18-dependent protein-protein interactions, as tested at 100 mM. Interaction and disruption threshold is indicated in the scale bar by a
black line. Levels of interaction and disruption above the threshold are demarked by ‘+’, and below the threshold by ‘ ‘. Tagged proteins were
expressed in the Leishmania tarentolae cell-free protein expression system. (D) Representative ALPHA-Screen concentration-response curve for SOX18
PPI disruption by Sm4. Data shown are mean ± s.e.m.
DOI: 10.7554/eLife.21221.002
The following figure supplements are available for figure 1:
Figure supplement 1. QC of SOX18 PPIs and effect of Sm4.
DOI: 10.7554/eLife.21221.003
Figure supplement 2. Differential disruption of SOXF PPI by Sm4.
DOI: 10.7554/eLife.21221.004
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Figure 2. Sm4 selectively affects SOX18 transcriptional output in vitro. (A) Schematic representation of the correlation analysis between genome-wide
TF ChIP-seq data and Sm4 affected genes from transcriptomics data. The chromatin around the transcription start sites (TSS) of Sm4 affected genes
(purple) was investigated for transcription factor binding peaks (grey), to calculate the ‘distance from TSS’ to closest binding site for a given
transcription factor. This distance from TSS was used as a proxy for the likelihood of transcriptional regulation, and thus make an association between
Sm4 affected genes and transcription factors. Included in the analysis where the ChIP-seq peaks of SOX18 and SOX7, and of all transcription factors
Figure 2 continued on next page
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Together, these results provide strong evidence that Sm4 selectively targets SOX18-mediated tran-
scription over other key endothelial transcription factors and SOX proteins.
To investigate whether Sm4 is also able to perturb Sox18 transcriptional activation in vivo, we
used the tg( 6.5kdrl:eGFP) transgenic zebrafish reporter line, previously validated as a readout for
the combined activity of Sox7 and Sox18 (Duong et al., 2014). We treated these larvae at 20 hr
post fertilization (hpf) and observed that Sm4 treatment significantly reduced SOX18-dependent
egfp transcript levels (61%), similar to the effects of combined sox7/18 depletion using morpholino
oligonucleotides (MO) (Figure 3A,B). Importantly, these zebrafish embryos developed normally and
we found no evidence of toxicity.
We then used a second transgenic zebrafish reporter line tg(Dll4in3:eGFP), which harbours a reg-
ulatory element located in the intron 3 of dll4 gene. The activity of this Dll4in3 enhancer does not
fully recapitulate the endogenous dll4 expression (Wythe et al., 2013; Sacilotto et al., 2013), but it
does provide a useful tool to study the combinatorial activity of Sox7, Sox18 and the Notch effector
Rbpj. Combined genetic interference with sox7, sox18 and rbpj has been shown to abolish Dll4in3
activation, while single or double MO knockdowns have a much milder effect (Sacilotto et al.,
2013). This mild repressive effect was recapitulated by treatment with Sm4 alone (Figure 3C,D). In
addition, when rbpj MO injections at suboptimal dose were combined with Sm4 treatment, the
repressive effect was significantly increased by 11.5% (Figure 3C,D). These data show that Sm4
interferes with Sox7/18 and Rbpj co-ordinated activation of the Dll4in3 enhancer. As a negative con-
trol in vivo, we used the Sox9-dependent tg(col2a1:yfp) reporter line, and observed that continuous
Sm4 treatment between 2 and 6 days post fertilization did not perturb the transcriptional activity of
Sox9 or the process of chondrogenesis (Figure 3—figure supplement 1). Together, this supports
the proposed mechanism of action for Sm4 as a selective SOX18 inhibitor in vivo.
To further demonstrate the small molecule inhibition of Sox18 function in vivo, we next investi-
gated whether Sm4 treatment would be able to cause a vascular phenotype, similar to that of sox7/
sox18 genetically disrupted zebrafish (Hermkens et al., 2015). This phenotype is characterised by
an arteriovenous specification defect, with reduced expression levels of arterial markers
(Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al., 2008). We treated zebrafish larvae
harbouring the arterial/venous reporter tg(fli1a:eGFP, 6.5kdrl:mCherry) with 1.5 mM Sm4 during the
relevant developmental window, starting from 16 hpf (Figure 3—figure supplement 2A). These lar-
vae acquired an enlarged posterior cardinal vein (PCV) at the expense of the dorsal aorta (DA)
(Figure 3E–G, Figure 3—figure supplement 2B), with arteriovenous shunts and incomplete trunk
circulation (Figure 3—figure supplement 2C,D). qRT-PCR analysis of blood vascular markers at 24
and 48 hpf revealed a significant dysregulation of arterial and venous genes in Sm4-treated condi-
tions compared to DMSO, particularly efnb2a, hey1 and efnb4a (Figure 3H, Figure 3—figure sup-
plement 2E).
Due to SoxF redundancy in arteriovenous specification, an A/V malformation phenotype is typi-
cally only observed in double loss of Sox7 and Sox18 function. Since Sm4 appeared to partially
Figure 2 continued
available from the Encode consortium (GATA2, c-FOS, c-JUN, CTCF, EZH2, MAX and c-MYC), performed in HUVECs. A random group of genes was
analysed as a control distribution as would be found by chance. (B) Sm4 affected genes were grouped into down-regulated (Sm4-down), unaffected
(Sm4-unchanged) and up-regulated (Sm4-up). The plots show the cumulative distribution of the distance between the TSS of Sm4 affected genes
(purple line, absolute fold change 2) and the closest genomic location of binding sites for SOX18, and control transcription factors SOX7 and GATA2.
The median distance from the TSS of differentially expressed genes to the nearest binding event of a given transcription factor was compared to the
median distance that is expected by chance from a random gene set (green line). Sm4 down regulated genes are significantly closer (bold) to the
SOX18 peaks, but not to SOX7 or GATA2 peaks.
DOI: 10.7554/eLife.21221.005
The following figure supplements are available for figure 2:
Figure supplement 1. Transcriptome-wide analysis of Sm4 selectivity in vitro.
DOI: 10.7554/eLife.21221.006
Figure supplement 2. c-JUN motifs are enriched in SOX18 binding sites.
DOI: 10.7554/eLife.21221.007
Figure supplement 3. Sm4 does not interfere with SOX9 or SOX17 activity in vitro.
DOI: 10.7554/eLife.21221.008
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interfere with Sox7-Rbpj and Sox7-Sox18 PPIs in vitro, we turned to a Sox7 specific phenotype to
assess whether this TF activity was inhibited by Sm4 in vivo. The hallmark of sox7 genetic disruption
is a short circulatory loop in the head formed by the lateral dorsal artery (Mohammed et al., 2013),
resulting in perturbed facial circulation (Hermkens et al., 2015). In presence of Sm4, we observe
minor malformation to the LDA reminiscent of a partial Sox7 loss of function phenotype (Author
response image 1). However, the blood circulation in the head is unaffected in Sm4-treated larvae,
signifying that a short circulatory loop has not fully formed. This phenotype supports of the conclu-
sion that Sox7 activity is only partially affected in presence of the small compound. Overall, these
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Figure 3. Sm4 blocks SoxF transcriptional activity in vivo. (A) Lateral brightfield (top) and fluorescent (bottom) images of 60 hpf zebrafish larvae carrying
the tg( 6.5kdrl:eGFP) SoxF reporter. Treatment was initiated at late stage (20 hpf) with either DMSO (negative control) or 1 mM Sm4, or larvae were
injected with morpholinos against both sox7 and sox18 (dMO sox7/18). Fluorescence intensity is shown as heatmap. Scale bar 200 mm (B) qRT-PCR
analysis on gfp transcripts levels in treated tg( 6.5kdrl:eGFP) larvae and sox7/18 morphants, showing reduction of activity on this transgene. (C) Lateral
view of zebrafish larvae carrying the tg(Dll4in3:eGFP) SoxF/Notch reporter that harbors multiple binding sites for Rbpj and SoxF transcription factors.
Larvae were injected with a morpholino against rbpj and/or treated with 2 mM Sm4 from 13 hpf. (D) qRT-PCR analysis on gfp transcripts in tg(Dll4in3:
eGFP) larvae, showing repression of combined SoxF/Notch activity in the Sm4-treated larvae. (E) Quantitation of embryonic lethality in larvae, treated
with Sm4 or DMSO control from early stage (16 hpf) until 72 hpf. (F) Penetrance of vascular phenotype (arteriovenous shunting) in 48 hpf larvae treated
with 1.5 mM Sm4 from 16 hpf. (G) Penetrance of circulation defect in 48 hpf larvae treated with 1.5 mM Sm4 from 16 hpf. (H) qRT-PCR analysis of
endogenous endothelial transcript levels at 48 hpf in larvae treated with 1.5 mM Sm4 at 16 hpf, relative to DMSO control (dotted line). Data shown are
mean ± s.e.m. *p<0.05, **p<0.01, ***p<0.001.
DOI: 10.7554/eLife.21221.009
The following figure supplements are available for figure 3:
Figure supplement 1. Sox9 activity is not perturbed by treatment in vivo.
DOI: 10.7554/eLife.21221.010
Figure supplement 2. Sm4 interferes with SoxF activity in vivo.
DOI: 10.7554/eLife.21221.011
Overman et al. eLife 2017;6:e21221. DOI: 10.7554/eLife.21221 7 of 18
Short report Biochemistry Developmental Biology and Stem Cells
results are congruent with the genome-wide inhibitory effects observed in vitro, demonstrating that
Sm4 selectively interfered with the transcriptional activity of Sox18 and SoxF-mediated vascular for-
mation in vivo.
As a final demonstration of the anti-angiogenic potential of Sm4 in a therapeutically relevant set-
ting, we next assessed its efficacy in a preclinical model of breast cancer. BALB/c mice were inocu-
lated with highly metastatic 4T1.2 mammary carcinoma cells into the mammary fat pad, and three
days were allowed for the engraftment of the tumor, after which treatment was initiated with either
25 mg/kg/day of Sm4, aspirin or vehicle PBS (Figure 4A). Aspirin was chosen as a negative control
because of the structural similarity to Sm4. Daily treatment was maintained for a duration of 10
days, after which the primary tumor was resected and effects on disease latency were monitored
(Figure 4A). As an indirect indication of target engagement, we first confirmed the expression of
Sox18 in the 4T1.2 tumor vasculature by in situ hybridization (Figure 4B). We next went on to mea-
sure Sm4 bioavailability during the course of the treatment. Sm4 was consistently detected in blood
plasma at two different time points, with a mean concentration increasing over time from 38.3 mg/
mL to 55.2 mg/mL (Figure 4C).
PBS vehicle- or aspirin-treated mice succumbed to the 4T1.2 tumor burden with a median latency
of 33 and 34 days respectively (Figure 4D), whereas Sm4-treated mice had a significant increase in
their overall survival with a median latency of 44 days (p-value<0.01). To further investigate what
could cause such an effect, the size of the tumors was monitored during the treatment, as well as
the formation of spontaneous lung metastases. While the size of the primary tumor was unchanged
by Sm4 treatment (Figure 4E), we found a 67% reduction in the mean number of lung metastases at
day 28 after tumor inoculation (Figure 4F).
To rule out any contribution by an inflammatory response as a result of surgery, we replicated the
study by performing a sham surgery, without excising the tumor (Figure 4—figure supplement 1A,
B). This approach confirmed that during the post-surgical period, primary tumor growth was unper-
turbed by Sm4 treatment and demonstrated that the combined effects of Sm4 with surgery-induced
inflammation is unlikely to be responsible for the increased survival.
In order to establish a correlation between the metastatic rate and a tumor induced vascular
response, we investigated the blood vessel density in the intra-tumoral and peri-tumoral regions
(Figure 4G, Figure 4—figure supplement 2). Whole tumors were sectioned, and brightfield micros-
copy revealed an overall reduction in blood vessel coverage, as indicated by the presence of red
blood cells (Figure 4G, asterisks). Further analysis using immunofluorescent staining for endothelial
cell markers ERG (nuclear) and Endomucin (EMCN, membranous), showed a significant decrease in
the number of endothelial cells (48%, p-value<0.05), as well as the volume of the blood vessels
(55%, p-value<0.01) in the tumors of Sm4-treated mice (Figure 4H,I, Figure 4—figure supplement
3). Using lymphatic specific markers PROX1 and podoplanin (PDPN), we also assessed the effect of
Sm4 on the tumor induced lymphangiogenic response, and found that the density of the tumor
associated lymphatic vessels was greatly reduced (65%, p-value<0.01) in treated conditions, as well
as the number of lymphatic endothelial cells (70%, p-value<0.001) (Figure 4—figure supplement 4).
This lymphatic response to Sm4-treatment is consistent with that of SOX18 loss of function during
lymphatic spread of solid cancers (Duong et al., 2012) Together, this demonstrates that Sm4
improved the outcome of induced breast cancer by interfering with tumor-induced neo-vasculariza-
tion and associated metastasis.
Induction of angio- and lymphangiogenesis is a hallmark of solid cancer, and is a critical step
towards enabling tumor metastatic dissemination. Conventional approaches to target transcription
factors have focused on interfering with oncogenes that are dysregulated to promote tumor cell
transformation (Gormally et al., 2014; Illendula et al., 2015; Moellering et al., 2009; Zhang et al.,
2012). Here, we validate a novel complementary strategy that relies on targeting a developmental
transcription factor from the host vasculature that can facilitate metastatic spread. Our results pro-
vide a proof of concept that targeting the transcription factor SOX18 with Sm4 is an effective molec-
ular strategy to interfere with the metastatic spread in a pre-clinical model of breast cancer.
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Figure 4. Metastasis and tumor vascularization is suppressed by Sm4 treatment. (A) Timeline of mouse model for breast cancer metastasis. 4T1.2 tumor
was inoculated at day 0, and resected at day 12. Sm4 (25 mg/kg/day), Aspirin (25 mg/kg/day) or vehicle control (PBS), was administered orally on a daily
basis from day 3 to day 12. Independent experiments were carried out to assess survival and metastatic rate. (B) Blood plasma concentrations of Sm4
during the course of the treatment scheme (day 7 and day 12) indicate good systemic delivery of the drug. (C) Expression of SOX18 in the vasculature
Figure 4 continued on next page
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Materials and methods
Experimental reproducibility
All data and statistical analysis in this study were generated from at least three independent experi-
ments unless indicated otherwise. Technical replicates were included in every experiment to reduce
background noise and detect technical anomalies. Samples of distinct experimental conditions were
not exposed to any specific method of randomization, and groups were assessed under non-blinded
conditions.
Plasmid preparation for cell-free expression
The genetically encoded tags used here are enhanced GFP (GFP), mCherry (Cherry) and cMyc (myc).
The proteins were cloned into the following cell free expression Gateway destination vectors respec-
tively: N-terminal GFP tagged (pCellFree_G03), N-terminal Cherry-cMyc (pCellFree_G07) and C-ter-
minal Cherry-cMyc tagged (pCellFree_G08) (Gagoski et al., 2015).The Open Reading Frames
(ORFs) corresponding to the human SOX7 (BC071947), SOX17, RBPJ (BC020780) and MEF2C
(BC026341) were sourced from the Human ORFeome collection version 1.1 and 5.1 or the Human
Orfeome collaboration OCAA collection (Open Biosystems) as previously described and cloned at
the ARVEC facility, UQ Diamantina Institute. The entry clones pDONOR223 or pENTR201 vectors
were exchanged with the ccdB gene in the expression plasmid by LR recombination (Life Technolo-
gies, Australia). The full-length human SOX18 gene was synthesized (IDT) and the transfers to vec-
tors was realized using Gateway PCR cloning.
Cell-free protein expression
The translation competent Leishmania tarentolae extract (LTE) was prepared as previously described
(Mureev et al., 2009; Kovtun et al., 2011). Protein pairs were co-expressed by adding 30 nM of
GFP template plasmid and 60 nM of Cherry template plasmid to LTE and incubating for 3 hr at
27˚C.
ALPHA-Screen assay
The ALPHA-Screen Assay was performed as previously described (Sierecki et al., 2014), using the
cMyc detection kit and Proxiplate-384 Plus plates (PerkinElmer). A serial dilution of each sample was
measured. The LTE lysate co-expressing the proteins of interest was diluted in buffer A (25 mM
HEPES, 50 mM NaCl). For the assay, 12.5 mL (0.4 mg) of Anti-cMyc coated Acceptor Beads in buffer
Figure 4 continued
of the tumor as shown by in situ hybridization. Scale bar 100 mm. (D) Survival of the mice was monitored (n = 6–12 mice per group). Improved survival in
Sm4-treated mice over both vehicle control and aspirin was analysed by Log-rank test (p<0.001). (E) No significant differences were found in tumor size
at any stage. (F) Metastatic tumor nodules on the surface of the lungs were quantified at day 28, before any of the vehicle control or Sm4-treated
animal had succumbed to the cancer burden. Data shown are mean ± s.e.m of 12–14 mice per group. (G) Vascular density was investigated on 300 mm
sections of whole tumors. Bright field images show the overall morphology of the tumor (outlined by dashed line) and presence of red blood cells,
marking the main blood vessels and haemorrhagic areas (asterisks). Scale bar 1 mm. (H) Double immunofluorescence staining for endothelial specific
markers ERG and Endomucin (EMCN) reveals the vascular patterning and penetration in the intra- and peri- tumoral regions. Left: whole tumor section
(scale bar 1 mm), middle and right: blow-up of boxed regions (scale bar 200 mm). (I) Quantitation of EMCN volume (blood vessel density) and ERG-
positive nuclei (number of endothelial cells) of n = 6 tumours per condition. Each data point represents the average of 3–4 representative regions
(boxed areas in panel H) per tumor. Mean ± s.e.m for both conditions are shown. *p<0.05, **p<0.01.
DOI: 10.7554/eLife.21221.012
The following figure supplements are available for figure 4:
Figure supplement 1. Sm4 efficacy is not a result of surgery-induced inflammation.
DOI: 10.7554/eLife.21221.013
Figure supplement 2. Penetrance of blood vessels into 4T1.2 tumors is impaired by Sm4.
DOI: 10.7554/eLife.21221.014
Figure supplement 3. Sm4-treated mice have decreased tumor vascular density.
DOI: 10.7554/eLife.21221.015
Figure supplement 4. Sm4 treatment disrupts tumour-induced lymphangiogenesis.
DOI: 10.7554/eLife.21221.016
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B (25 mM HEPES, 50 mM NaCl, 0.001% NP40, 0.001% casein) were aliquoted into each well. This
was followed by the addition of 2 mL of diluted sample and 2 mL of biotin labeled GFP-Nanotrap in
buffer A. The plate was incubated for 45 min at RT. Afterward, 2 mL (0.4 mg) of Streptavidin coated
Donor Beads diluted in buffer A, were added, followed by incubation in the dark for 45 min at RT.
The ALPHA-Screen signal was obtained on an Envision Multilabel Plate Reader (PerkinElmer), using
the manufacturer’s recommended settings (excitation: 680/30 nm for 0.18 s, emission: 570/100 nm
after 37 ms). The resulting bell-shaped curve is an indication of a positive interaction, while a flat line
reflects a lack of interaction between the proteins. The measurement of each protein pair was
repeated a minimum of three times using separate plates. The Binding Index was calculated as:
BI ¼
I Ineg
Iref Ineg
h i
x 100
For each experiment, I is the highest signal level (top of the hook effect curve) and Ineg is the low-
est (background) signal level. The signals were normalized to the Iref signal obtained for the interac-
tion of SOX18 with itself.
For PPI disruption assay, protein pairs expressed in LTE were incubated for 1 hr with 100 mM Sm4
or DMSO alone (0.7% DMSO final). 100 mM Sm4 or DMSO was also added to buffer B. PPI disrup-
tion was calculated as: 1  ISm4
IDMSO
 
x 100.
For IC50 determination, the assay was identical but a dilution range of Sm4 was used (0.3 to 300
mM). Percentage of interaction was calculated as: ISm4
IDMSO
x 100. Data from at least three independent
experiments were fitted in GraphPad Prism (RRID: SCR_007370) version 6.0 using 3-parameter non-
linear regression.
Cell culture and transfection
COS-7 cells were purchased from ATCC (CRL-1651, RRID: CVCL_0224) cultured at 37˚C, 5% CO2 in
DMEM (Life technologies, 11995) with added FBS, sodium pyruvate, L-glutamine, penicillin, strepto-
mycin, non-essential amino acids and HEPES (N-2-hydroxyethylpiperazine-N’ 2-ethanesulfonic acid).
COS-7 cells were transfected for 4–6 hr, and incubated for another 24 hr before lysis and luciferase
assay (Perkin Elmer, 6016711). Human umbilical vein endothelial cells (HUVECs) were purchased
from Lonza Australia (CC-2519A). HUVEC for ChIP-MS, ChIP-seq and RNA-seq analyses were trans-
fection for 7 hr and incubated another 14 hr. During small molecule treatment, cells were grown in
medium containing low serum (0.4% FBS). HUVECs were cultured at 37˚C, 5% CO2 in EGM-2 media
supplemented according to the EGM-2 bullet kit instruction (Lonza, CC-3162). Cells for were grown
in 35 mm dishes to 80–90% confluency, and transfected with plasmid mouse pSG5 Sox18, plasmid
pSG5 cMyc-Sox18, or plasmid cMyc using X-tremegene 9 DNA transfection reagent (Roche,
06365787001) according to the manufacturer’s instructions. All cell lines were tested negative for
mycoplasma contamination.
Chromatin immunoprecipitation
ChIP experiments were performed as previously described (Schmidt et al., 2009). Immunoprecipita-
tion was performed using Anti-cMyc (Cell Signaling, #2276, RRID: AB_2314825) on HUVECs overex-
pressing cMyc-tagged SOX18.
ChIP-seq and analysis
Following IP, DNA amplification was performed using TruSeq ChIPseq kit (Illumina, IP-202–1012),
using 0.5 mM of the universal reverse PCR primer and the forward PCR primer containing the index
sequence of choice in 50 mL 1 x NEBNext High-Fidelity PCR Master Mix (New England Biolabs,
M0541). The number of PCR cycles ranged from 13 to 18, depending on the ChIP efficiency. The
PCR product was purified using AMPure beads (1.8 vol) and eluted in 20 mL of resuspension buffer
(Tris-Acetate 10 mM pH 8). The library was quantified using the KAPA library quantification kit for
Illumina sequencing platforms (KAPA Biosystems, KK4824) and 50 bp single end reads were
sequenced on a HiSeq2500 following the manufacturer’s protocol. Illumina fastq files were mapped
to the GRCh37/UCSC hg19 genome assembly using bowtie, and peaks were called using MACS ver-
sion 2.1.0. using input. To avoid false positive peaks calling due to the cMyc epitope, ChIP-seq with
the cMyc epitope only were performed in parallel to SOX18-cMyc ChIP-seq and peaks called in
these experimental conditions were substracted to the peaks called in the SOX18-cMyc conditions.
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Genomic Regions Enrichment of Annotations Tool (GREAT, RRID: SCR_005807)) was used to analyse
the functional significance of cis-regulatory regions. ChIP-seq data are available in the ArrayExpress
database (www.ebi.ac.uk/arrayexpress, RRID: SCR_002964) under accession number E-MTAB-4480
(SOX7) and E-MTAB-4481 (SOX18).
ChIP-MS (RIME)
ChIP-MS experiments were performed as previously described (Mohammed et al., 2013). Peptides
common between SOX18-cMyc and the negative control (cMyc-only) were binned and only peptides
that were uniquely detected in the SOX18-cMyc transfected cell were considered for analysis.
RNA-seq and analysis
Quadruplicate samples were processed for whole transcriptome sequencing using TruSeq stranded
total RNA library prep kit (Illumina). Reads were mapped to the hg19 reference human genome
using STAR aligner (Dobin et al., 2013), and only uniquely aligned reads were considered. Tran-
scripts were assigned to genes using htseq_count (HTseq package) (Anders et al., 2015), and differ-
ential expression was calculated using DEseq2 (Love et al., 2014). Genes with adjusted
p-value<0.05 were considered significant.
Differentially expressed genes were identified between Sm4-treated and DMSO control in
SOX18 over-expressing cells, and separated in up-regulated and down-regulated (DOWN) genes.
The locations of their transcription start sites (TSS) were correlated to the locations of transcription
factors binding events that are available from the ENCODE consortium (RRID: SCR_006793), and
from the SOX18 and SOX7 ChIP-seq experiment we performed in this study. To ensure that the
TSSs were independent, a TSS was allowed to only be assigned to 1 ChIP-seq peak. Transcripts
with 2 fold absolute fold change (log2FC  1 or   1) were included for distance to TSS analysis.
The median distance between the TSSs and binding events was compared to the expected distance
of a set of randomly selected genes to obtain the median ratio. The control set of genes was
selected from the pool of genes expressed in HUVECs so that they had a similar distribution of
expression levels. To ensure that no bias was introduced by potential co-regulation of genes by
SOX18 and any other transcription factor analysed, we subtracted genes with SOX18 peaks from the
analyses for other transcription factors. The reverse analysis was also performed, subtracting genes
containing c-JUN peaks from the analysis for SOX18. RNA-seq data are available in the ArrayExpress
database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-4511.
Quantitative RT-PCR
Total RNA was extracted using RNeasy mini kit (Qiagen, 74106) according to the manufacturers pro-
tocol, including on column DNA digestion. cDNA was synthetised from 1 mg of purified RNA using
the high capacity cDNA reverse transcription kit (Life Technologies, 4368813). Amplification and
quantitation of target cDNA was performed in technical triplicate of at least three biological repli-
cates using the SYBR green (Life Technologies, 4312704) methods. Reactions were run in 10 mL in
384-well plates using the ViiA 7 Real-Time PCR system. Housekeeper genes (b-actin for tg(Dll4in3:
eGFP), ef1a for tg( 6.5kdrl:eGFP), chd5 for tg(fli1a:eGFP,  6.5kdrl:mCherry), RPL13 and GAPDH
for HUVECs) were selected based on the stability of their expression throughout the set of experi-
mental conditions, or chosen on grounds of their vascular expression to normalize to endothelial cell
content. Primer efficiencies were calculated using LinRegPCR, and amplification data was analysed
using ViiA7 software and the Q-gene PCR analysis template.
Zebrafish aquaculture and analysis
Zebrafish were maintained as previously described (Hogan et al., 2009), and all procedures involv-
ing animals conformed to guidelines of the animal ethics committee at the University of Queensland
(IMB/030/16/NHMRC/ARC/HF) or were approved by local ethical review and licensed by the UK
Home Office (PPL 30/2783 and PPL 30/3324). The tg( 6.5kdrl:eGFP), tg(fli1a:eGFP, 6.5kdrl:
mCherry) and tg(Dll4in3:GFP) were previously described (Sacilotto et al., 2013; Duong et al., 2014;
Lawson and Weinstein, 2002).
Dechorionation was performed by treatment with 25 mg/mL or 5 mg/mL pronase for 2 hr, or over-
night, respectively. Zebrafish larvae were anesthetized using 0.01% tricaine. Representative larvae
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were embedded in 0.5% low-melting point agarose and imaged with the Zeiss LSM 710 confocal
microscope.
Zebrafish in situ hybridization and sectional analysis
Wholemount zebrafish (28 and 48 hpf) in situ hybridization was performed as previously described
(Thisse and Thisse, 2008) with probe templates for dab (Song et al., 2004) and ephrinB2a
(Durbin et al., 1998). Yolk sac was removed prior to addition of in 70% glycerol. For transverse sec-
tions, whole larvae where embedded in 4% agarose, sectioned at 150 mm using the Leica VT1000 S
vibrating microtome. Imaging was performed on the Olympus BX-51 brightfield microscope (ISH),
and Zeiss LSM 510 confocal microscope. For fluorescent images, larvae were DAPI-stained before
embedding.
Small molecule treatment and morpholino injections
All treatment with putative small molecule inhibitors, and corresponding control conditions, were
performed in the presence of low concentration of DMSO (1% v/v) to achieve reliable homoge-
neous solutions, and were prepared from 10 mM DMSO stock. For cell culture, small molecules
were added to fresh media directly following transfection and cells were grown in this media until
time-point of cell harvesting. For in vivo experiments involving zebrafish, compound treatment was
initiated at the designated timepoints by replacing the media, and media + compound was
refreshed daily for the duration of the experiment. PTU treatment (0.003%) was done in parallel with
the small molecules to block pigment formation when necessary. Previously published and validated
morpholino oligomers against sox7, sox18 (Herpers et al., 2008) and rbpj (Sacilotto et al., 2013)
were micro-injected into single cell zebrafish zygotes at 5 ng for experiments performed with tg
(6.5kdrl:eGFP) and tg(fli1a:eGFP, 6.5kdrl:mCherry), and 0.125–0.15 pmol suboptimal concentrations
for experiments performed with tg(Dll4in3:eGFP).
Mice and mouse model
BALB/c wild-type (WT) were purchased from Walter and Eliza Hall Institute for Medical Research and
used between the ages of 6 and 10 weeks. Mouse 4T1.2 mammary carcinoma cells were cultured in
complete RPMI with 10% FBS in a 5% CO2 incubator. 510
4 4T1.2 tumor cells were inoculated into
the fourth mammary fat-pad of BALB/c WT mice as previously described (Mittal et al., 2014).
Briefly, on day three after tumor implantation, mice were orally gavaged daily for 10 days with 25
mg/kg of body weight Sm4, aspirin or vehicle PBS. Tumor size was measured with a digital caliper
as the product of two perpendicular diameters. Blood plasma was collected from mice on day 7 and
12, and Sm4 concentrations were analyzed using a 4000 Qtrap LC-MS/MS system mass spectrome-
ter. On day 12, mice were anesthetised to surgically remove primary tumor, or mice were put
through surgery procedure with no excision of the primary tumor, and the wound was closed with
surgical clips. Tumors were collected in formalin for histology. Lungs were harvested on day 28 and
fixed in Bouin’s solution for 24 hr and metastatic tumor nodules were counted under a dissection
microscope. Survival of the mice was monitored in experiments where the lungs were not harvested.
Groups of 6 to 14 mice per experiment were used for experimental tumor assays, to ensure ade-
quate power to detect biological differences. All experiments were approved by the QIMR
Berghofer Medical Research Institute Animal Ethics Committee (P1505).
For quantitation of the vasculature in the tumors, fixed tissues were embedded in 4% agarose
and sectioned all the way through at 300 mm on a Leica VT1000 S vibrating microtome. Sections
were collected on glass slides and imaged for bright field analysis on the penetration of perfused
vessels. Subsequently, immunofluorescent staining was performed on sections using anti-mouse
Endomucin (cat# sc-53941, RRID: AB_2100038), ERG (cat# ab92513, RRID: AB_2630401), PROX1
(AngioBio cat#11–002, RRID: AB_10013720) and Podoplanin (AngioBio cat#11–033, AB_2631191)
antibodies. Whole tumor sections were imaged by acquiring a series of images along the z-axis using
a 10x objective on a Zeiss LSM 710 confocal microscope. Subsequently, high-resolution images were
captured using a 20x objective on 3–4 separate regions from each tumor, to account for heteroge-
neity of the vascular density within the tumors and minimise bias. Raw image files with identical
dimensions (1274.87 mm x 1274.87 mm x 89.05 mm) were loaded into Imaris (Bitplane, RRID: SCR_
007370), and processed using ‘spots’ function to count ERG or PROX1- positive nuclei and ‘surface’
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to calculate volume or area of Endomucin or Podoplanin positive vessels. For each tumor (n = 6),
counts from the multiple regions were averaged and the data was plotted in Graphpad Prism 6.
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